康柏西普注射液联合532 nm激光全视网膜光凝术治疗糖尿病视网膜病变的临床效果

Abstract
Figure/Table
References (28)
Related Citation (9)

Download: PDF (422 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Conbercept Injection combined with 532 nm laser panretinal photocoagulation in the treatment of diabetic retinopathy (DR) and its influence on fundus microcirculation. Methods Eighty-two patients (96 eyes) with DR admitted to the Ninth People’s Hospital of Suzhou City from March 2017 to March 2020 were selected and they were divided into observation group (41 cases, 50 eyes) and control group (41 cases, 46 eyes) according to the random number table method. The control group was treated with 532 nm laser panretinal photocoagulation, and the observation group was treated with Conbercept Injection on the basis of the control group. Retinal fovea thickness (CMT), best corrected visual acuity (BCVA), intraocular pressure, clinical efficacy, and fundus microcirculation were compared between the two groups. Results There were no significant differences in CMT, BCVA, and intraocular pressure between the two groups before treatment (P ＞ 0.05); six months after treatment, CMT in both groups was decreased, and the observation group was lower than that of the control group (P ＜ 0.05), BCVA was increased, and the observation group was higher than that of the control group (P ＜ 0.05). There was no statistical significance in intraocular pressure between the two groups (P ＞ 0.05). Six months after treatment, there was a significant difference in clinical effects between the two groups (P ＜ 0.05). There were no statistically significant differences in plasma viscosity (PV), erythrocyte aggregation index (EAI), erythrocyte deformation index (EDI), erythrocyte sedimentation rate (ESR), and hematocrit (Hct) between the two groups before treatment (P ＞ 0.05); six months after treatment, PV, EAI, EDI, ESR, and Hct in both groups were decreased (P ＜ 0.05), and which in the observation group were lower than those in the control group (P ＜ 0.05). There was no significant difference in the incidence of complications between the two groups (P ＞ 0.05). Conclusion The treatment of DR patients with conbercept injection combined with 532 nm laser panretinal photocoagulation can reduce CMT, improve vision, and has a definite effect, and it can improve the fundus microcirculation.

Key words： Conbercept Laser photocoagulation Diabetic retinopathy Fundus microcirculation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Jing SHEN Yifei▲

Cite this article:

XU Jing SHEN Yifei▲. Clinical effect of Conbercept injection combined with 532 nm laser panretinal photocoagulation in the treatment of diabetic retinopathy#br#[J]. 中国医药导报, 2021, 18(36): 73-76.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I36/73

[1] Hammes HP. Diabetic retinopathy： hyperglycaemia，oxidative stress and beyond [J]. Diabetologia，2018，61（1）：29-38.
[2] Simó-Servat O，Hernández C，Simó R. Diabetic retinopathy in the context of patients with diabetes [J]. Ophthalmic Res，2019，62（4）：211-217.
[3] 张天垚，李强.血糖波动与糖尿病视网膜病变的相关性[J].医学研究生学报，2020，33（11）：114-118.
[4] Vujosevic S，Aldington SJ，Silva P，et al. Screening for diabetic retinopathy：new perspectives and challenges [J]. Lancet Diabetes Endocrinol，2020，8（4）：337-347.
[5] Berrocal MH，Acaba LA，Chenworth ML. Surgical innovations in the treatment of diabetic macular edema and diabetic retinopathy [J]. Curr Diab Rep，2019，19（10）：106-111.
[6] 刘静，夏天，郭艺，等.532nm激光PRP联合羟苯磺酸钙对DR患者眼底微循环及黄斑厚度的影响[J].国际眼科杂志，2020，20（8）：1343-1346.
[7] Lu Q，Lu L，Chen B，et al. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy [J]. Can J Ophthalmol，2019，54（3）：291-296.
[8] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南（2014年）[J].中华眼科杂志，2014，50（11）：851-865.
[9] 李洪霞.国际标准视力表[M].南昌：江西科学技术出版社，2010：131-135.
[10] 周婉瑜. 糖尿病性视网膜病变[M].上海：科学技术文献出版社，2011：102-104.
[11] 闫配，张晓红，张莉，等.HMW-ADP、TNF-α、VEGF与糖尿病视网膜病变的关系研究[J].中国医药导报，2019， 16（9）：112-115.
[12] Karam T，Kamath YS，Rao LG，et al. Diabetic retinopathy in patients with diabetic foot syndrome in South India [J]. Indian J Ophthalmol，2018，66（4）：547-550.
[13] 王露露，孙艳红，韦企平，等.糖尿病视网膜病变激光治疗的并发症及其防治[J].国际眼科杂志，2019，19（3）：62-65.
[14] Salongcay RP，Silva PS. The role of teleophthalmology in the management of diabetic retinopathy [J]. Asia Pac J Ophthalmol （Phila），2018，7（1）：17-21.
[15] 郭伟宾，杨江萍，侯娇娇，等.糖尿病视网膜病变的危险因素分析[J].解放军医药杂志，2018，30（6）：46-48.
[16] 郝艳，周志华.血清胱抑素C与2型糖尿病视网膜病变及周围血管病变相关性分析[J].临床军医杂志，2020， 48（1）：90-92.
[17] 蔡璇，毛一鸣，王相宁，等.增生型糖尿病视网膜病变玻璃体切割术后再出血的治疗和观察[J].国际眼科杂志，2018，18（8）：158-161.
[18] 马雄雄，王东艳，王理论.不同波长激光光凝联合雷珠单抗治疗非增生型糖尿病视网膜病变临床效果分析[J].临床误诊误治，2019，32（11）：91-96.
[19] 陆骏，秦瑜，肖文玮，等.玻璃体腔内注射雷珠单抗联合532nm激光光凝治疗缺血型视网膜静脉阻塞患者的疗效观察[J].河北医学，2019，25（5）：732-737.
[20] 陈震，张雨，聂玉红.全视网膜激光光凝联合不同药物对PDR患者视网膜厚度、BCVA和N1波潜伏期的影响比较[J].临床和实验医学杂志，2019，294（14）：1552-1554.
[21] 康建芳，孙昊，冯军.康柏西普玻璃体内注射联合532nm激光全视网膜光凝治疗糖尿病视网膜病变[J].中国临床研究，2019，32（9）：1189-1192.
[22] 郑通美.眼底激光联合康柏西普治疗糖尿病视网膜病变效果分析[J].中国医药科学，2021，246（6）：215-217， 228.
[23] 王雪飞，王洪军，江瀚然，等.视网膜激光光凝联合抗VEGF药物治疗视网膜静脉阻塞疾病的疗效观察[J].中国现代医生，2019，57（33）：1-3，7.
[24] 张金平，任新军，郑传珍，等.玻璃体切割手术完毕注射康柏西普辅助治疗增生型糖尿病视网膜病变玻璃体积血的疗效观察[J].中华眼底病杂志，2020，36（2）：105-109.
[25] Johannesen SK，Viken JN，Vergmann AS，et al. Optical coherence tomography angiography and microvascular changes in diabetic retinopathy：a systematic review [J]. Acta Ophthalmol，2019，97（1）：7-14.
[26] Mao JB，Wu HF，Chen YQ，et al. Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy [J]. Int J Ophthalmol，2018，11（7）：1217-1221.
[27] 刘莉，唐敬巧.康柏西普联合激光辅助治疗糖尿病视网膜病变的临床观察[J].中国药师，2019，22（4）：108-111.
[28] 石少华，徐帆，李敏.康柏西普辅助玻璃体切割治疗PDR的临床研究[J].国际眼科杂志，2020，20（5）：118-121.